All Healthcare articles
-
BlogHealth care winners and losers in the Covid era
US health care stocks have seen many twists and turns during the Covid-19 crisis years, mirroring shifting investor attentions to the new growth opportunities arising from the massive investments and advances in vaccines, testing and other technological innovations within the medical arena.
-
White papers
Life Science in Germany
It is now time to provide a detailed analysis of the real estate sector for life sciences companies. This market segment is attracting everincreasing interest from property developers, investors and financiers. It comes as no surprise that medical technology, pharmaceuticals and biotech companies have gained significant prominence over the last two years in view of their huge contribution to the control of the Covid-19 pandemic.
-
Asset Manager News
Primonial REIM Germany successfully carries out a healthcare real estate transaction on behalf of Primovie, a retail investor fund managed by Primonial REIM France
Primonial REIM Germany today announces that it has acquired Futura III, a seven-asset portfolio in Germany dedicated to assisted living. The seller is Senioren-Wohnen Holding from which an acquisition of a first portfolio was already made in 2019 (Futura I portfolio)
-
White papers
China Is an Outlier in a COVID-Accepting World
China may shift from a zero-COVID policy only when the costs of containing the coronavirus exceed the benefits. A prolonged outbreak could crimp growth acceleration. The main growth stimulus efforts are likely to come from fiscal sources as policy shifts from deleveraging to pro-growth. Beijing could incentivize a capital ...
-
White papers
If Sanctions Didn’t Stop the War, They Can Still Shape the Peace
After Ukraine’s allies decide how much to ratchet up pressure on Russia, they will face tough choices on how to ratchet down.
-
Asset Manager News
KGAL acquires Charles Square Center in Prague
Grünwald, 24.02.2022 – KGAL Investment Management GmbH & Co. KG has acquired the Charles Square Center in Prague, which includes offices, retail, restaurants and healthcare space, on behalf of a pan-European fund. The city centre property with a total of almost 20,000 square metres of leasable space has a roster of international, renowned tenants. The seller was Commerz Real.
-
Video
2022: An even brighter future for disruptive tech
The pandemic has sped up a transformation in technology that would otherwise have taken years, triggering a sea change in how we work, buy and communicate. Advances in, for example, cloud computing, the internet of things and artificial intelligence are affecting industries as diverse as financial services, healthcare and consumer goods and creating opportunities for investors.
-
Video
Synthetic Biology: Investing in the Science of Sustainability
If the technology for making diabetes medicine hadn’t changed since the 1930s, today we’d need an area larger than the surface of the earth for raising pigs, harvesting insulin from their pancreases to help hundreds of millions of diabetics around the world.
-
White papers
Omicron Soon to Be the Dominant Variant in the U.S…Is This Strain the Way Out of the Pandemic?
We thought it might be helpful to frame our latest thinking on the SARS-CoV2 Omicron variant now that we have seen more data out of South Africa on the evolution of this viral variant.
-
White papers
How investing in biotech can help achieve the SDGs
From pioneering therapies to renewable food sources, biotechnology has the potential to address many of humanity’s greatest challenges, as aligned to the United Nations’ Sustainable Development Goals (SDGs).
-
White papers
Omicron: The Reason to Seriously Consider Getting a Third COVID-19 Vaccine Shot
Pfizer data suggests a third dose of Comirnaty (COVID-19 vaccine) appeared to increase neutralizing antibodies 25-fold against the Omicron variant, a level suggesting protective immunity against severe COVID-19.
-
Blog
Russell 1000 dodges the worst of the Omicron meltdown
The discovery of a new Covid-19 variant in late-November ratcheted up already high anxieties about renewed lockdowns across Europe, worsening inflation and central-bank tightening, triggering a panic sell off that left few of the world’s equity markets and stock sectors unscathed.
-
White papers
Geopolitics of the vaccine: variance risks
Covid-19 vaccines have been rolled out for a year now. Despite official commitments to provide access to effective jabs to all countries, production constraints and national priorities have resulted in uneven distribution, with some countries close to 100% vaccination rates while others are still below 5%.
-
White papers
Real Estate Convictions - November 2021
In a world dominated by uncertainty, the recovery in the global economy continues. With the on-going vaccination of the general population and booster campaigns remaining a strategic priority, to avoid the introduction of new health restrictions that would deteriorate growth in late 2021 and early 2022, the deterioration of short-term prospects has come from China.
-
White papers
Novo Nordisk Throws Its Weight Behind Patients With Obesity And Diabetes
The world’s obesity and sugar-high problems have healthcare budgets bursting at the seams.
-
White papers
Battling the superbugs
Antimicrobial resistance (AMR) is growing, although the risk too often goes unmanaged or ignored. Yet the ramifications for public health are huge.
-
Research Report
Climate crisis in focus in EOS’s Q3 Public Engagement Report
With scientists calling for urgent action on climate change following another year of devastating wildfires and floods, November’s COP26 summit is considered critical.
-
-
White papers
Innovations in Sustainability Are Reshaping the Future of Plastic
Balancing health and environmental concerns with the material’s utility.
-
White papers
5 trends driving the future of biotech
I am often asked about my outlook for biotechnology in light of how rapidly vaccines were developed for COVID-19. I would say this may be a sign of things to come for the industry. I’ve been seeing a renaissance that’s led to an explosion of novel drug targets in recent years.
